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Abstract The objective of this study was to evaluate
patients’ satisfaction with acute treatment of migraine with
frovatriptan or almotriptan by preference questionnaire. One
hundred and thirty three subjects with a history of migraine
with or without aura (IHS 2004 criteria), with at least one
migraine attack in the preceding 6 months, were enrolled
and randomized to frovatriptan 2.5 mg or almotriptan
12.5 mg, treating 1–3 attacks. The study had a multicenter,
randomized, double blind, cross-over design, with treatment
periods lasting \3 months. At study end patients assigned
preference to one of the treatments using a questionnaire
with a score from 0 to 5 (primary endpoint). Secondary
endpoints were pain free and pain relief episodes at 2 and 4 h,
and recurrent and sustained pain free episodes within 48 h.
Of the 133 patients (86%, intention-to-treat population) 114
of them expressed a preference for a triptan. The average
preference score was not significantly different between
frovatriptan (3.1 ± 1.3) and almotriptan (3.4 ± 1.3). The
rates of pain free (30% frovatriptan vs. 32% almotriptan) and
pain relief (54% vs. 56%) episodes at 2 h did not significantly
differ between treatments. This was the case also at 4 h (pain
free: 56% vs. 59%; pain relief: 75% vs. 72%). Recurrent
episodes were significantly (P \ 0.05) less frequent under
frovatriptan (30% vs. 44%), also for the attacks treated
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within 30 min. No significant differences were observed in
sustained pain free episodes (21% vs. 18%). The tolerability
profile was similar between the two drugs. In conclusion, our
study suggests that frovatriptan has a similar efficacy of
almotriptan in the short-term, while some advantages are
observed during long-term treatment.
Keywords Migraine  Frovatriptan  Almotriptan 
Patient preference
Introduction
Millions of people worldwide suffer from migraine, a
chronic, recurrent, disabling, neurovascular disorder [1].
Triptans are selective serotonin 5-HT1B/1D receptor ago-
nists, generally considered as safe and effective acute
migraine drugs [2, 3]. Since the introduction of the first
triptan, sumatriptan, almost 20 years ago, several triptans
with different pharmacokinetic and pharmacodynamic
properties, and thus different efficacy and safety profiles,
have been developed [3, 4]. Some of them are labeled as
fast triptans and share similar characteristics with suma-
triptan, the prototype triptan, displaying a rapid dose-
dependent efficacy, with a higher risk of adverse effects,
while others seem to have a more delayed onset of the
relieving effect on migraine symptoms, but a more pro-
longed duration of action and a reduced rate of recurrent
migraine attacks [5].
Frovatriptan is one of the most recent triptans, devel-
oped in order to provide a drug with a clinical potential for
a long duration of action and a low likelihood of side
effects and drug interactions [6–8]. Randomized clinical
studies and post-marketing surveys showed significantly
improved effectiveness and tolerability ratings with
frovatriptan as compared to previous acute therapies,
including triptans, analgesics and non-steroidal anti-
inflammatory drugs [9–12].
In the recent past, three double-blind, randomized, head-
to-head trials have compared safety of frovatriptan with
that of sumatriptan [13], and efficacy and safety of frova-
triptan with that of rizatriptan [14] and zolmitriptan [15]. In
order to add new information to existing ones, a cross-over
study was setup to directly compare in the same subjects
efficacy and tolerability of frovatriptan versus almotriptan.
The latter is a relatively fast acting triptan, which showed
in several randomized studies, lack of clinically relevant
pharmacokinetic interaction with other drugs, adverse
reactions rate similar to placebo, and good anti-migraine
efficacy as compared to other triptans [16, 17].
The study had been designed to assess efficacy by
analyzing traditional migraine treatment endpoints and also
by considering patient’s preference to treatment [18].
Methods
Study population
The study included subjects of male or female gender,
18–65 years old, with a current history of migraine with or
without aura, according to International Headache Society
(IHS) 2004 criteria, and with at least one, but no more than
6 migraine attacks per month for 6 months prior to entering
the study [19].
Patient could not be enrolled in the study in case of:
(a) uncontrolled hypertension; (b) ischemic heart disease;
(c) cardiac arrhythmias or symptomatic Wolff-Parkinson-
White syndrome; (d) previous stroke or transient ischemic
attack; (e) severe liver or renal impairment; (f) any other
severe or disabling medical condition; (g) history of alco-
hol or analgesic or psychotropic drug abuse; (h) known
hypersensitivity to study drugs; (i) previously demonstrated
inadequate response to at least two triptans; (j) current use
of propranolol or ergothamine (and its derivatives) as a
prophylactic agent; (k) current use or use in the previous
2 weeks of MAO-inhibitors; (l) use of either test medica-
tion to treat any one of the last three episodes of migraine;
(m) other headaches that have been lasting for more than
6 days. Pregnant women and breast-feeding mothers were
excluded as well, while women with childbearing potential
but not practicing an effective method of birth control were
to be submitted to a pregnancy test, if clinically indicated.
Written informed consent was obtained from all patients
prior to their inclusion into the study. The study was
approved by the Independent Institutional Review Boards
of the study centers.
Study design
This was a multicenter, randomized, double blind, cross-
over study, including 12 centers across Italy (see Appendix).
Each patient received frovatriptan 2.5 mg or almotriptan
12.5 mg in a randomized sequence: after treating 3 episodes
of migraine in no more than 3 months with the first treat-
ment, the patient had to switch to the other treatment. After
treating 3 episodes of migraine in no more than 3 months
with the second treatment, each patient was asked to assign
preference to one of the treatments according to a ques-
tionnaire with a preference score graded from 0 to 5.
The study involved three visits and each patient’s par-
ticipation time in the study had not to exceed 6 months
from randomization. Subjects having no migraine episodes
during one of the two observation periods were excluded
from the study.
During the randomization visit, after signing written
informed consent, subjects provided a medical treatment
and migraine history. A physical and neurological
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examination and pregnancy test (if appropriate) were per-
formed. Blood pressure and heart rate were measured for
all subjects. The degree of migraine-associated disability
(MIDAS questionnaire) was also completed. At the end of
the visit a headache diary documenting characteristics of
headache pain and associated symptoms was dispensed
with study medication. Subjects were instructed to treat at
least 3 migraine episodes occurring in no more than
3 months and to come for the second visit. On this occasion
use of concomitant medications and occurrence of adverse
events (from diary) were checked, blood pressure and heart
rate were recorded, and a pregnancy test performed, if
deemed necessary. The same procedures were carried out
at the end of the second study treatment period or at the
early withdrawal visit, together with the administration of
the patient’s preference questionnaire.
Patients were instructed to take one dose of study medi-
cation as early as possible after the onset of migraine attack.
If insufficient relief had been obtained after 2 h, patients
were allowed to take a second dose of study medication, with
a maximum daily intake of two doses. In case of insufficient
relief 1 h after the intake of the second dose of the study
medication, patients were allowed to take a rescue medica-
tion. Alternate rescue medication could not include triptans,
or contain ergotamine or its derivatives, or propranolol.
Data analysis
The primary study endpoint was the between-treatment
comparison of the direction and average strength of pref-
erence at the end of the study, measured on a scale from
0 (no preference) to 5 (strong preference) [14, 15]. The rate
of patients expressing a preference and reason for prefer-
ence were also calculated.
The hypothesis was that a superiority of one treatment
against the other had to occur in the presence of a differ-
ence of ?1.0 with a standard deviation of 2.375. Consid-
ering a two-tailed test with a 0.05 significance level and an
80.7% power, the estimated number of patients to be ran-
domized was 120 (including a 25% drop-outs), 60 for each
treatment group.
The primary analysis population was the intention-to-
treat population, formed by all patients randomized to any
of the two treatment sequences, having not positively
refused to receive either study treatment, having treated at
least one episode of migraine with both medications and
who expressed their preference at study termination. The
per-protocol population, i.e., patients of the intention-to-
treat population displaying no protocol violations, was used
for confirmatory analysis.
Secondary study endpoints were quantified according to
IHS Guidelines [19]. In summary, these endpoints were:
(a) the number of pain free episodes at 2 h (absence of
migraine episodes at 2 h after intake of one dose of study
drug ± rescue medication), (b) recurrence, assessed as sta-
ted in the protocol, i.e., an episode of migraine occurring
within 48 h from the previous one, after a period without
migraine, and also more appropriately as an episode which is
pain free at 2 h and headache of any severity returns within
48 h; (c) the number of sustained pain free episodes within
48 h (migraine attack which is pain free at 2 h, does not recur
and does not require the use of rescue medication within
48 h), (d) and the number of pain relief episodes at 2 h
(defined as a decrease in migraine intensity from severe or
moderate to mild or none). Evaluation of the rate of pain free
episodes, recurrence and sustained pain free episodes was
also done for the subgroup of subjects with migraine attacks
treated no more than 30 min from their onset (early intake).
Tolerability analysis was applied to all randomized
patients, by calculating the incidence of adverse events
during the treated attacks and changes in vital signs during
the study.
Continuous variables were summarized by computing
average values and standard deviation (SD), while cate-
gorical variables by computing the absolute value and the
frequency (as percentage). Preference scores were com-
pared between treatment groups by analysis of variance.
Secondary endpoints were compared between groups by
generalized estimating equation analysis. Kaplan–Meyer
curves for cumulative hazard of recurrence over the 48 h
were also drawn. P value refers to the statistical significance
of between-treatment difference. The level of statistical
significance was kept at 0.05 throughout the whole study.
Results
Baseline demographic and clinical data
The flow diagram of participants throughout the study is
shown in Fig. 1. Overall, 133 patients were screened and
randomized to active treatment. Of these patients, 113
completed the study and 20 prematurely withdrew from the
study because of failure to treat one episode of migraine
(n = 9), lost to follow-up (n = 4), withdrawal of consent
(n = 3), dissatisfaction to assigned treatment (n = 1),
occurrence of an adverse event (n = 1), protocol violation
(n = 1), lack of cooperation (n = 1).
The intention-to-treat population consisted of 114
patients, while the per-protocol population included 63
patients: 51 patients were considered major protocol vio-
lation (13 patients treated less than 3 attacks and 38 made
wrong use of rescue medication) (Fig. 1). Table 1 shows
main demographic and clinical characteristics of the
patients of the intention-to-treat population at the time of
randomization. Most of the subjects enrolled (84%) were of
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a female gender, this explaining the high rate of premen-
strual attacks (70% of patients treated at least one pre-
menstrual attack). The vast majority of attacks were of
moderate or severe intensity (97% of patients had at least
one moderate or severe attack). Baseline data for the per-
protocol population did not differ from those of the
intention-to-treat population (data not shown).
Primary end-point
In the 114 subjects of the intention-to-treat population
the preference score averaged to 3.1 ± 1.3 for frova-
triptan and to 3.4 ± 1.3 for almotriptan (P = NS); 63%
of patients expressed a clear preference for a triptan
(29% for frovatriptan and 34% for almotriptan, P = NS).
The proportion of patients with a moderate to very good
grade of overall satisfaction was slightly, but not sig-
nificantly, larger under frovatriptan (75% vs. 70%
almotriptan).
The most common reasons for preferring one triptan
were the rapid action (51.4% frovatriptan and 55.0%
almotriptan), prevention of aggravation (13.5% and 2.5%),
and reduction of severity (13.5% and 15.0%): no significant
differences were observed between treatments for these
data. Additional preference results will be published in
details elsewhere. Results of per-protocol analysis for the
primary end-point were superimposable to those of the
intention-to-treat population (data not shown).
Fig. 1 Flow diagram of
participants throughout the
study
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Secondary end-points
Results of the analysis of secondary end-points for the
intention-to-treat population are summarized in Table 2.
At 2 h, the rates of pain free (30% with frovatriptan vs.
32% with almotriptan) and pain relief episodes (54% with
frovatriptan vs. 56% with almotriptan) were not signifi-
cantly (P = NS) different between the two treatments.
Sustained pain free episodes were also similar between
the two groups (21% frovatriptan vs. 18% almotriptan;
P = NS).
Conversely, the rate of recurrent episodes at 48 h was
significantly (P \ 0.05) lower under frovatriptan, both
when defined according to the protocol (28% vs. 34%
almotriptan) or to IHS criteria (30% vs. 44%). This was the
case also when recurrence was expressed as a cumulative
hazard ratio over the observation period (Fig. 2, left panel).
A superiority of frovatriptan over almotriptan with
regards to headache recurrence was also observed for the
255 (38%) attacks (83 patients, 73% of patients of the
intention-to-treat population) for which the drug was taken
within 30 min from the onset of the episode (Table 3;
Fig. 2, right panel). In this subgroup of the main study
population rate of pain free episodes at 2 h and of sustained
pain free episodes, did not significantly differ between the
two treatments (Table 3).
Analysis of the per-protocol population for the second-
ary end-points gave results similar to those of the intention-
to-treat population (data not shown).
Tolerability
Analysis of tolerability was carried out in 123 patients.
Adverse events were reported by 13 patients during
treatment with frovatriptan and by 12 patients during
treatment with almotriptan (10.6% vs. 9.8% of treated
patients) for an overall number of 52 adverse events (28
under frovatriptan and 24 under almotriptan). Most of the
events were of a mild or moderate intensity (89%), and no
serious adverse events were recorded during the study. No
patients under frovatriptan prematurely withdrew from the
study while 1 patient under almotriptan did.
Table 1 Demographic and
clinical data of the 114 patients
of the intention-to-treat
population at the time of
randomization
Data are shown as mean (±SD),
or absolute (n) and relative
frequency (%)
a Numbers refer to number and
frequency of attacks as respect
to overall number of attacks in
the female patients
b Numbers refer to number and
frequency of attacks as respect
to overall number of attacks
n = 114
Age (years, means ± SD) 40 ± 10
Females (n, %) 96 (84)
Height (cm, means ± SD) 165 ± 6
Weight (kg, means ± SD) 65 ± 12
Age at onset of migraine (years, means ± SD) 18 ± 8
Migraine attack duration [2 days (n, %) 29 (25)
MIDAS score (means ± SD) 23 ± 16
No use of triptans in the previous 3 months (n, %) 93 (82)
Premenstrual attacks (n, %)a 155 (28)
Patients with at least one premenstrual attack (n, %) 67 (70)
Migraine with aura (n, %)b 64 (10)
Patients with at least one attack with aura (n, %) 24 (21)
Moderate or severe attacks (n, %)b 532 (80)
Patients with at least one moderate or severe attack (n, %) 111 (97)
Study drug intake \30 min (n, %)(2) 255 (38)
Patients with at least one study drug intake \30 min (n, %) 83 (73)
Table 2 Results for the secondary study endpoints
Frovatriptan Almotriptan P
Pain free episodes at 2 h 99 (30) 104 (32) NS
Recurrent episodes (protocol definition) 93 (28) 115 (34) \0.05
Recurrent episodes (IHS definition) 30 (30) 46 (44) \0.05
Pain relief episodes at 2 h 143 (54) 144 (56) NS
Sustained pain free episodes 69 (21) 58 (18) NS
Data are shown for the intention-to-treat population and reported as absolute (n) and relative (%) frequency. P refers to the statistical significance
of the difference between the two treatment groups
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Side effects attributed to study treatment were 31 (60%
of total events) and occurred in 4 patients during frova-
triptan and in 6 patients during almotriptan treatment
(P = NS). As reported in Table 4 the number of drug-
related adverse events was not significantly different
between the two groups, though a larger prevalence of
angina-like symptoms (palpitation or tachycardia, thoracic
constriction or tightness) was observed under almotriptan
(7 vs. 1 under frovatriptan).
Treatment was accompanied by no relevant changes in
vital signs, ECG or results of cardiovascular examination.
Discussion
Acute treatment of migraine with frovatriptan and almo-
triptan resulted in similar proportions of pain relief and
pain free episodes at 2 h, indicating a superimposable
short-term efficacy between the two triptans. However,
frovatriptan had a more sustained relieving effect on
migraine symptoms, with lower rates of headache recur-
rence over the 48 h than almotriptan. Interestingly, results
observed in the subgroup of subjects treating attacks within
30 min after their occurrence was similar to those of the
main study population. These differences in efficacy
between the two study drugs may be largely attributable to
the different pharmacokinetics of the two drugs. Indeed,
almotriptan has a slightly shorter time to maximum con-
centration than frovatriptan [5, 6], this possibly explaining
why major benefits in migraine treatment are usually
reported under almotriptan when the drug is administered
within an hour of migraine onset and particularly when
pain is mild [16, 17]. Frovatriptan has a longer half-life
than almotriptan (25–26 h vs. 3–4 h), and has one of the
greatest 5-HT1B binding receptor affinity among triptans
and multiple pathways metabolism, which might explain
why frovatriptan, unlike almotriptan, greatly reduced the
risk of migraine recurrence [20].
Patient’s preference for one drug or the other did not
differ between the study treatments. Frovatriptan was
chosen mainly because of the rapid onset of action (54.1%
of patients), reduction in pain severity (13.5%), and pre-
vention of aggravation (13.5%). The fact that more than
half of the patients preferred frovatriptan for its rapid
activity and that similar short-term efficacy was observed
between the two groups of patients, also in the subgroup
with early drug intake, confirms what was recently reported
in a long-term open label study, namely that frovatriptan
may provide a remarkably fast and high headache response
in more than one-third of migraineurs, labeled as ‘‘rapid
responders’’ [21].
Previous direct comparisons between frovatriptan and
almotriptan are lacking. However, our results are in line with
published indirect comparisons, based on placebo controlled
studies [22, 23]. In a review of five randomized, double-
blind, placebo-controlled studies, headache response rate at
2 h (pain relief) for frovatriptan ranged between 38% and
40% before placebo correction, while it was slightly higher
in our study (54%) [22]. In six studies, pain relief at 2 h under
Fig. 2 Cumulative hazard of
recurrence over the 48 h during
treatment with frovatriptan or
almotriptan, in the 114 patients
of the whole study population
and for attacks for which the
drug was taken within 30 min
from the onset of the episode
Table 3 Results for the secondary study endpoints in the subgroup of
83 patients with early study drug intake (\30 min)
Frovatriptan Almotriptan P
Pain free episodes at 2 h 48 (35) 42 (32) NS
Recurrent episodes (protocol) 22 (20) 33 (32) \0.05
Recurrent episodes
(IHS definition)
16 (21) 29 (38) \0.05
Sustained pain free episodes 32 (27) 23 (21) NS
Data are shown for the intention-to-treat population and reported as
absolute (n) and relative (%) frequency. P refers to the statistical
significance of the difference between the two treatment groups
366 J Headache Pain (2011) 12:361–368
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almotriptan averaged to 60–61% before placebo correction
(56% in our study) [9, 22–24].
In previous studies, frovatriptan was more effective than
placebo in rendering patients pain free at 2 h (12% of
patients) [6]. In two different meta-analyses, rate of pain
free at 2 h with almotriptan was 35–36%, a proportion very
similar to that of our study (31%) [22, 23]. The additional
finding of our study is that proportion of pain free episodes
at 2 h (30%) under frovatriptan was much higher than that
observed in the abovementioned placebo-controlled stud-
ies, but it was similar to that found in two recently pub-
lished studies with the same design and a similar sample
size [14, 15]. In such studies rate of pain free ranged
between 26% and 33% with frovatriptan, a frequency
similar to that of the two comparators (rizatriptan 39% and
zolmitriptan 31%).
Headache recurrence at 24 h averaged to 17% with
frovatriptan [9] and to 25–27% with almotriptan in former
meta-analyses [9, 22]: in our study headache recurrence
was assessed more properly within the 48 h, as indicated
by IHS guidelines [19], and was significantly less frequent
under frovatriptan than almotriptan (30% vs. 44%). This is
in line with results of open label naturalistic studies and
meta-analyses of placebo-controlled efficacy studies,
which suggest that in a real world setting frovatriptan is
associated with a lower rate of migraine recurrence than
with other triptans [25]. Post-marketing surveys also indi-
cate that the long duration of action of frovatriptan appears
to confer other benefits such as greater patient satisfaction,
with over 80–90% of patients and physicians rating
frovatriptan therapy as very good or good, both in terms of
efficacy and tolerability [10–12, 25].
The good long-term efficacy of frovatriptan shown in
our study seems to support indication of frovatriptan for
those patients requiring a prolonged duration of action,
with a sustained effect and less side effects. Pharmaco-
kinetic features of frovatriptan may make it suitable for
patients who need prophylaxis such as in menstrual-related
migraine and in patients with long-duration or recurrent
migraine attacks [24, 26, 27]. In these patients early use of
frovatriptan has been shown to be associated with a greater
benefit [12, 28]. Conversely, almotriptan may be useful in
those patients requiring a rapid pain relief [16, 17].
In terms of tolerability, no significant difference in the
prevalence of adverse drug reactions was observed between
the two study treatments, although a trend to a higher
prevalence of angina-like symptoms was observed under
almotriptan. The similar tolerability profile between the
two drugs might be regarded as a positive feature in favor
of frovatriptan, since it is well known that almotriptan is
one of the best tolerated triptans, showing a placebo-like
tolerability profile [16, 21].
In conclusion, our multicenter, randomized, double-
blind, head-to-head study suggests that frovatriptan and
almotriptan are similarly preferred in patients with acute
migraine attacks and have a similar antimigraine efficacy.
However, due to its long half-life, on the long-term,
frovatriptan showed a lower risk of recurrence than
almotriptan.
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Table 4 Distribution of absolute numbers of drug-related adverse events between the two treatment groups, in the 123 patients of the safety
population
Frovatriptan Almotriptan All
Intensity Intensity
Mild Moderate Severe Mild Moderate Severe
Asthenia – 2 – – – – 2
Nausea or vomiting – 2 – – 3 – 5
Palpitation or tachycardia 1 – – 2 – 1 4
Thoracic constriction or tightness – – – – 2 2 4
Sensation of being dazed – – 1 – – – 1
Dry or sticky mouth 4 – – – 3 – 7
Abdominal pain or diarrhea – – – – 1 1 2
Anxiety – – – 1 1 – 2
Other – 2 1 1 – – 4
Total adverse events 13 18 31
Total patients (%) 4 (3.3) 6 (4.9) 10 (8.2)
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